Details

Autor(en) / Beteiligte

• Friedrich, Chloé
• Zalmaï, Loria
• Gay, Juliette
• Coude, Marie Magdeleine
• Bravetti, Clotilde
• Vazquez, Romain
• Temple, Marie
• Duroyon, Eugénie
• Darnige, Luc
• Decroocq, Justine
• Alary, Anne Sophie
• Kosmider, Olivier

Titel

PCR‐Fluo‐ASXL1‐FA: A fast, sensitive and inexpensive complementary method to detect ASXL1 mutations in haematological malignancies

Ist Teil von

• International journal of laboratory hematology, 2022-10, Vol.44 (5), p.928-933

Ort / Verlag

Chichester: Wiley Subscription Services, Inc

Erscheinungsjahr

2022

Quelle

Wiley Online Library - AutoHoldings Journals

Beschreibungen/Notizen

• Introduction The additional sex combs like 1 (ASXL1) gene is frequently mutated in a number of haematological neoplasms. The c.1934dupG, known to be the most common alteration in ASXL1, is associated with poor clinical outcome. A systematic determination of ASXL1 mutational status in myeloid malignancies is therefore necessary for prognostic stratification. Methods Because direct sequencing is not sensitive and next‐generation sequencing (NGS) is time‐consuming, expensive and sometimes does not allow the detection of the c.1934dupG, we have developed a fragment analysis assay, complementary to NGS, that allows the detection of c.1934dupG mutation in addition to other nearby insertions/deletions of ASXL1 located close to it. We called this assay the “PCR‐Fluo‐ASXL1‐FA.” Results First, we evaluated the efficiency of our approach compared to NGS and Sanger. We showed that “PCR‐Fluo‐ASXL1‐FA” could detect all insertional mutations of ASXL1 located on its area, with a high sensitivity (1.5%). Then, we have illustrated the interest of this technique by three concrete cases. Discussion In summary, we have established a fragment analysis approach, which can detect most ASXL1 mutations, in particular the c.1934dupG, in a sensitive, fast and inexpensive manner. We therefore recommend the synchronous use of this method with NGS, to ensure complete detection of all clinically relevant ASXL1 mutations in patients suffering with myeloid neoplasms.